<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by BioFutures Initiative on Medium]]></title>
        <description><![CDATA[Stories by BioFutures Initiative on Medium]]></description>
        <link>https://medium.com/@biofuturesinitiative?source=rss-fb90287f2c22------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/2*I6WaR8GQx6XGYLeC-_rrcw.png</url>
            <title>Stories by BioFutures Initiative on Medium</title>
            <link>https://medium.com/@biofuturesinitiative?source=rss-fb90287f2c22------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 02:59:57 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@biofuturesinitiative/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Strengthening the development of European BioApplications will be key for a sustainable Biofuture]]></title>
            <link>https://medium.com/@biofuturesinitiative/strengthening-the-development-of-european-bioapplications-will-be-key-for-a-sustainable-biofuture-f77033768557?source=rss-fb90287f2c22------2</link>
            <guid isPermaLink="false">https://medium.com/p/f77033768557</guid>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[future]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[sustainability]]></category>
            <category><![CDATA[europe]]></category>
            <dc:creator><![CDATA[BioFutures Initiative]]></dc:creator>
            <pubDate>Fri, 19 Jun 2020 00:14:47 GMT</pubDate>
            <atom:updated>2020-06-19T17:18:04.268Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NaLih0D1t4QJzSG2RDtexw.png" /></figure><h3><em>“We need more great entrepreneurial projects, especially in biotechnology.”</em></h3><p><strong>A sustainable biofuture requires bio-based innovations. Synthetic Biology is increasingly recognised for its revolutionary impact to deliver ground-breaking and sustainable innovations. However, the development of such innovations is cost and time-intensive. Established companies with a natural interest in BioApplications from the pharmaceutical industry and the agricultural sector rely more and more on external players such as startups and university spin-offs to introduce innovation. For Europe to be at the heart of the upcoming biology-based transformation of the economy.</strong></p><p>To better understand the direction bio-based entrepreneurship is heading and what makes the European innovation ecosystem attractive and what are the bottlenecks for startups in this field, this blog shares the experiences from three different young company representatives, namely Victor Sayous (CTO @ Gourmey), Jeremie Blache (CEO @ Pili) and Patrick Torbey (CTO @ Neoplants). The insights were gathered during a panel, chaired by Thomas Landrain (CEO @JOGL), which was held during the Sustainable BioFuture Initiative’s first<a href="https://www.deeptechweek.com/agenda-deeptechweek/?oaq%5Buid%5D=49118124"> virtual meetup on March 11</a>, with key opinion leaders in synthetic biology &amp; biotechnology from Europe present.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bglM0zn5IaaDjJXZTm6aWQ.png" /><figcaption>Source: European Commission <a href="https://ec.europa.eu/growth/sites/growth/files/ris2019.pdf">Regional Innovation Scoreboard 2019</a></figcaption></figure><p><strong>Thomas: <em>Where do you think deep tech and in particular BioApplications are heading?</em></strong></p><p><strong>Victor:</strong> I think that from our generation, born in the 80s and 90s, there are more and more scientists who are using biotechnology to help tackle the environmental crisis. This is a huge reason to be optimistic. Especially, if we have an adapted EU regulatory framework allowing responsible innovations around GMOs and Venture Capitalists ready to invest, we will see some beautiful ideas and projects rise in Europe.</p><p><strong>Jeremie: </strong>I also think that biotechnology is more and more involved in solving environmental issues. BioApplications hold particular promise in the materials and chemistry sector. The combination of biotech and chemistry permits companies to develop a wide range of more sustainably produced products following the path of the food industry developing sustainable alternatives for animal-based proteins.</p><p><strong>Patrick: </strong>My vision depends a lot on the time scale we are talking about.<strong> </strong>I think we are at the very beginning of an era of biotechnology. A good analogy would be the computer science field in the 70s. Similarly to that time, we barely understand the (genetic) code, tools are not yet standardized, etc. We are at the beginning of what I think is going to be a huge exponential affecting many different domains. Over the next ten years, we’re going to see existing technologies and biotech merging into amazing products. I think the convergence of technologies is what people often miss when predicting the future. Those future technologies, and products thereof, will touch a large number of people through B2B and B2C business models. Future biotech companies will design products that can be found in every household and in every meal. That’s very different from the currently existing biotech products.</p><p><strong>Thomas: <em>What made you build your company in France? Did you think about leaving Europe at one point?</em></strong></p><p><strong>Jeremie:</strong> Indeed, the location where to incorporate the company was a big question. We decided to stay for two main reasons.</p><p>Firstly, funding tools to create your own science-based startup are accessible in Europe. A lot of grants are available that support a variety of entrepreneurial projects. Our company is based around plant chemistry which is of strategic interest to France that has a lot of biomass to valorize. Getting money for such a project in the Silicon Valley would have likely been more difficult. Also, the research tax credit is a very interesting financial incentive to stay in France.</p><p>Secondly, in the south of France there exists a platform called <a href="https://www.toulouse-white-biotechnology.com/">Toulouse White Biotechnology</a> cluster. We were given the chance to settle there and use a lot of expensive equipment and available expertise. This unique kind of combination of equipment and expertise is difficult to find elsewhere and was extremely important to us as we are not a spin-off from an academic laboratory but instead started from scratch with just the idea and a “very dirty” proof of concept.</p><p><strong>Patrick:</strong> Along those lines I would like to add that public grants allow you to double more or less any private investment you may receive. The availability of public grants to create your deep tech company is a major location advantage of France but also more generally Europe. Additionally, we have an amazing biotech talent pool that regular tech startups may not have. Those talents can be recruited from all the other countries in Europe because of the freedom of movement in Europe.</p><p>What France in particular needs to improve upon is the availability of expensive equipment. As a spin-off you may keep access to the academic laboratories and their equipment but what about startups starting from scratch that need access to 20 machines that cost $1,000,000 each? They need these machines for a few minutes a day but can’t afford them. What are they supposed to do? There should be a huge governmental effort to further democratize the access to biotechnologies by providing communal laboratories and relevant other infrastructure.</p><p><strong>Victor:</strong> I don’t have many things to add because our reasons to stay in France have already been named: support through public grants from e.g. BPI France and the amazing talent pool. The missing access to equipment is indeed a problem. The necessary equipment exists in many academic research labs in France but remains inaccessible for private research. There is not much exchange between public and private research labs — in fact there is a cultural problem. In France it feels like public and private research envy each other, there is ill-will towards each other and resources are not shared at all. This might be one of the main drawbacks with the USA or China where these borders seem to exist to a much lesser extent.</p><p><strong>Thomas:</strong> <strong><em>One could say the academic world is less attractive for the young generation, less and less scientists pursue an academic research career. Do you believe that entrepreneurship provides a new way of advancing knowledge and technology for the greater good?</em></strong></p><p><strong>Victor:</strong> If you want to pursue a scientific career in France it is indeed very difficult to do so in academia. You have to be excellent and lucky, several high-level publications, suffer through many short term contracts as postdoc before having a chance for a stable (and independent) position at a public research center or university. Therefore, I believe applying for funding for a proof of concept study and to develop a prototype is a new way of pursuing one’s own research interests.</p><p><strong>Patrick:</strong> I totally agree that entrepreneurship is going to be huge, especially in biology, and I encourage anyone who is disappointed by academia to try to join young deep tech companies or create one. Those deep tech companies are doing world class science. The only difference is that science is not conducted to write a high-level publication but instead leads to a real world product. I would say in some instances that is even more interesting.</p><p><strong>Jeremie:</strong> I agree and would like to add for those people that think there is not enough money out to create your own startup it is the contrary. There is public and private money available to get started, we just lack great projects. So for any person who thinks about creating your own deep tech company please do so because we need more great entrepreneurial projects, especially in biotechnology.</p><p>Based on these discussions we encourage you to continue the conversation, and would like to hear from you as we plan for our next event. Please r<a href="https://forms.gle/B5G8FU8FZV7XC7jQ6">egister here</a> for more information on upcoming events and follow the process on our first community whitepaper.</p><p><strong>About BioFutures</strong></p><p>The Biofutures Initiative was co-created by <a href="https://igem.org/">iGEM</a> &amp; <a href="https://hello-tomorrow.org/">Hello Tomorrow</a> as an opportunity for researchers, startups &amp; companies in biotech to meet and discuss what infrastructure is needed to facilitate a sustainable Biofuture in the European Union.</p><p>Biotechnological advances have accelerated over the past two decades. Our ability to read and write DNA has provided us with unprecedented abilities to engineer biology, also known as synthetic biology. Fundamental biotechnologies are increasingly transformed into B2B/B2C products, as well as new medical therapies and diagnostics. We believe that biology will create the next innovation wave and that it has the potential to positively impact many of the Sustainable Development Goals.</p><p>Therefore we will bring together key stakeholders to define priority actions that aim to better connect the EU biotech-ecosystem, promote the expansion of local bioeconomies, prepare and educate future generations.</p><p>We invite biotech startups, corporates, researchers with ideas to strengthen the EU biotech ecosystem to join the initiative. <a href="https://forms.gle/B5G8FU8FZV7XC7jQ6">Register here</a> to receive updates about our activities or to join as ecosystem partner. You can also follow our progress on <a href="https://twitter.com/bio_futures">Twitter</a>.</p><p>[The interview/panel session was edited for clarity.]</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f77033768557" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Creating the Infrastructure & Regulation for a Sustainable Biofuture]]></title>
            <link>https://medium.com/@biofuturesinitiative/creating-the-infrastructure-regulation-for-a-sustainable-biofuture-7eec7a9dd9b2?source=rss-fb90287f2c22------2</link>
            <guid isPermaLink="false">https://medium.com/p/7eec7a9dd9b2</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[infrastructure]]></category>
            <category><![CDATA[policy]]></category>
            <category><![CDATA[sustainability]]></category>
            <category><![CDATA[europe]]></category>
            <dc:creator><![CDATA[BioFutures Initiative]]></dc:creator>
            <pubDate>Wed, 06 May 2020 18:23:25 GMT</pubDate>
            <atom:updated>2020-05-06T18:26:05.136Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jHKkrMSiy50Zfh62FecJNg.png" /></figure><h4>“My vision would be that we manage to build a network of infrastructure together in Europe. One that interacts between the academic and private sector in a very fluid manner.”</h4><p>We are living in extraordinary times, and we have been for the better part of last 200 years. Thanks to biobased innovations such as vaccinations, sanitation and modern agriculture we have been able to eradicate diseases, improve our life expectancies and feed a growing population.</p><p>We have gotten so good at it this, that until very recently many of us have taken it for granted and forgotten the biological systems that we live with in and depend upon. Now more than ever we have the opportunity to reflect upon the role of biology in our society and how we can work with it to face global challenges in health, food and water and create a more sustainable biofuture.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5FqJV6qDm7OTI7bxKGh1qg.png" /><figcaption>Figure 1. The layers of Sustainable Development Goals that form the basis for a circular bioeconomy strategy. Source: Azote Images for Stockholm Resilience Centre.</figcaption></figure><p>We began this discussion in our first <a href="https://www.deeptechweek.com/agenda-deeptechweek/?oaq%5Buid%5D=49118124">virtual meetup on March 11</a>th, with key opinion leaders in European synthetic biology &amp; biotechnology to gather inspiration to progress towards these shared goals.</p><p>A key topic of interest for the participants was the infrastructure and regulatory requirements to help us achieve this and to support the scalability of solutions. Thankfully we were joined by an expert panelists; Olivier Rolland from <a href="https://www.toulouse-white-biotechnology.com/en/">TWB</a>, Cindy Gerhardt from <a href="https://www.biotechcampusdelft.com/">DSM Biotech Campus Delft</a>, Simon Trancart from <a href="http://www.altar.bio/">Altar</a> and Alex Nielsen from <a href="https://rebbls.dk/">REBBLS</a> to discuss this and more. The discussion was moderated by Will Wright from <a href="https://igem.org/">iGEM</a>.</p><p><strong>Will: <em>“Olivier, we have several biotech market leaders in Europe, especially within large scale fermentation. Yet, Europe is not often considered to be a front runner in Biotech Innovation. Why is that?”</em></strong></p><p><em>“In my opinion there are three 3 main reasons.</em></p><p><em>I would say the first is access to </em><strong><em>capital</em></strong><em>, second is the </em><strong><em>capabilities </em></strong><em>and the third one is </em><strong><em>regulation.</em></strong></p><p><em>With regards to capital, it takes time and money to develop the process around scale-ups. The funding is critical and you could get much more in the US compared to Europe. More in terms of size of the funding, the accessibility as well as in the number of opportunities. This goes all the way from VCs to federal funding opportunities like DARPA who invest in biotech research and development.</em></p><p><em>The second reason are </em><strong><em>capabilities</em></strong><em>.</em></p><p><em>The capabilities in the US are much more concentrated. Not only physically but also within specific organizations including</em> <em>companies. Start-ups like </em><a href="https://www.ginkgobioworks.com/"><em>Ginkgo</em></a><em> and </em><a href="https://www.zymergen.com/"><em>Zymergen</em></a> <em>have raised 100’s of million of dollars enabling them to build the integrated capabilities in-house. Another example are national labs such as the </em><a href="https://www.jbei.org/"><em>Joint BioEnergy institute</em></a><em>.</em></p><p><em>In Europe, I think we are a bit delayed in trying to shape our own research infrastructure. However we see some promising developments, in particular a EC-funded project called </em><a href="http://roadmap2018.esfri.eu/projects-and-landmarks/browse-the-catalogue/eu-ibisba/"><em>IBISBA-ESFRI</em></a><em> which aims at building a research infrastructure on synthetic biology and industrial biotechnology that will be distributed over nine countries, the idea being to really accelerate projects from the proof of concept to Scale-Up.</em></p><p><em>The last one is </em><strong><em>regulation</em></strong><em>.</em></p><p><em>Regulation is somehow less stringent for businesses outside Europe. In particular as it relates to GMM/GMO [Genetically Modified Microorganisms / Genetically Modified Organisms] which results into an easier market access in the US or China as opposed to Europe. An example is the stand that has been taken by EU regulators to regulate CRISPR Cas9-edited plants as GMO’s. At the same time, the US regulates CRISPR Cas9-edited plants as non-GMO, leading to different ways of using those on the market.</em></p><p><em>I will finish on one comment here of </em><strong><em>what we could do in Europe.</em></strong></p><p><em>We are pretty advanced in terms of carbon neutrality as a continent. However, I think that both the US and China have managed to link biotechnology to other strategic stakes. Such as energy independency or food independency which has a ‘pulling ability’ and has attracted a large amount of interest and funding. Such links are necessary.</em></p><p><em>I don’t think we should repeat what has been done in the US in terms of massive investments of private capital in startups. That will not be able to provide all the biotech R&amp;D needed in the end. They will always have to take a product focus, as opposed to a service one as it relates to the role of an infrastructure, in order to break even.</em></p><p><em>My vision would be that we manage to build a network of infrastructure together in Europe. One that interacts between the academic and private sector in a very fluid manner. With some standardisation of our procedures between institutes we would be able to accelerate biotech development. We could then benefit from the European Union funding to really keep all partners at the state of the art and share the risks and funds between different member states and organizations”</em></p><p>Olivier Rolland from <a href="https://www.toulouse-white-biotechnology.com/en/">TWB</a>.</p><p><strong>Will: <em>“Cindy, What are the the greatest challenges in creating an integrated supply chain from the lab to scale-up production in your opinion?”</em></strong></p><p><em>“I also think there are </em><strong><em>three main challenges.</em></strong></p><p><em>The first is in general the </em><a href="https://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/annexes/h2020-wp1415-annex-g-trl_en.pdf"><strong><em>technology readiness levels </em></strong></a><strong><em>(TRLs).</em></strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*CboJxtfnb_gpCDpFFRtsUg.png" /><figcaption>Technology readiness levels (TRL), image based on <a href="https://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/annexes/h2020-wp1415-annex-g-trl_en.pdf">https://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/annexes/h2020-wp1415-annex-g-trl_en.pdf</a></figcaption></figure><p><em>We have really promising technologies but their low TRL is often an issue. It’s hard for companies to invest if the TRL is too low and then the universities have to continue to work on it. In that case, universities often have difficulties to scale up and find commercial actors to join. We see the same difficulties with pilot plants that, despite promising results, don’t have the money to invest in new hardware for innovative technologies to the second development stage.</em></p><p><em>The second challenge is around </em><strong><em>infrastructure investment.</em></strong></p><p><em>In Europe, we have established players that have been there for long time. Some of these companies have factories that are more than 100 years old. They could gradually upgrade them, but companies often opt to build new facilities, or venture with partners that have production facilities that are easier to modify. They would rather venture into finding partners outside of Europe to use their newer production facilities. Investment into into large scale production facilities is a big issue because of the high risk and long return on investment.</em></p><p><em>Then we have the third point, the </em><strong><em>value chain.</em></strong></p><p><em>The whole value chain is scattered around Europe. When you think about it, the most effective way to organise the production and scale up is when you combine all the elements of the of the value chain in one location. However, the access to the raw materials and feedstocks in Europe is sometimes highly scattered. Especially access to primary biomass is often not co-located with locations where the final products are manufactured. Or, with locations where biobased innovations are being developed. So there’s a scattered landscape across the many European countries, and connecting those value chains remains a big challenge. On the other hand, biotech may provide excellent opportunities for smaller scale, local initiatives to upgrade local feedstock, byproducts or waste.”</em></p><p>Cindy Gerhardt from <a href="https://www.biotechcampusdelft.com/">DSM Biotech Campus Delft.</a></p><h3>“I think GMOs are a really fundamental question to address to open up for the full potential of synbio. If we really want to solve the grand sustainability issues at scale, then we need the biotech community to be more progressive on this issue.”</h3><p><strong>Will: <em>“Simon, aside from physical infrastructure what EU regulations have positively or negatively affected your business?”</em></strong></p><p><em>“In our field, the GMO </em><strong><em>regulation</em></strong><em> is more strict than in other areas. In the case of my company, we are in a particular situation, because we harness natural selection for making better microbes instead of using genetic engineering. Therefore, we develop non-GMO organisms. Because the microbes we improve are non-GMO in a majority of cases, I can witness an increasing interest for our technology in Europe because of the strict regulation.</em></p><p><em>Unfortunately, interactions between stakeholders — consumers, industrialists, politics and lawmakers — are tense and the debate does not progress. In my opinion, this situation prevents us from financing more industrial biotech companies. In cosmetics markets for instance, regulation does not ban GMOs but large companies and investors tend not invest in these projects because the risk is too high that, eventually, the end consumer boycotts the use of GMOs or that the regulation changes.</em></p><p><em>For these reasons, I think that EU regulations have negatively affected biotech businesses in general. But it’s also the </em><strong><em>public perception</em></strong><em>. Both are weaknesses for our industry.</em></p><p><em>I also think we lack efficient financing institutions to bring money into longer-term high-risk projects. Whereas health biotech is a mature industry with well-defined and standardized stages of development which creates exit opportunities for investors, industrial biotech investments are more risky because the exit may only happen when a scientific start-up has become an industrial producer. The limited life cycle of private equity and venture capital funds may not suffice. That said, this situation is not specific to Europe.</em></p><p><em>Now, the regulation can have a significant impact on the competitiveness of industrial biotech processes. As they aim at replacing our massive use of fossil resources by sustainable conversion of feedstocks that are in our hand, they contribute at mitigating climate change and make us independent. In that perspective, Europe could pioneer incentive regulations in the frame of the Green Deal and shape tomorrow’s world.”</em></p><p>Simon Trancart from <a href="http://www.altar.bio/">Altar</a>.</p><p><strong>Will: <em>“Alex, what do you think is the key topic to address in regards to large scale biotech innovation?”</em></strong></p><p><em>“</em><strong><em>Regulation</em></strong><em> is key in my opinion. Seeing the struggle of new breakthrough biotechnology, with huge potential impact for more sustainable industries, due to lack of the right regulatory frameworks. A positive example can be found with Novozymes, which has been very successful in scaling up biosynthetic enzymes for use in detergents. A major growth driver for them has been the ban on certain surfactants that could be replaced by enzymes to protect ecosystems. So we can see that to switch demand it started with proper regulation.</em></p><p><em>In this respect, I think GMOs are a really fundamental question to address to open up for the full potential of synbio. If we really want to solve the grand sustainability issues at scale, then we need the biotech community to be more progressive on this issue. We need to take a bolder position in demystifying and demonstrating its potential for good. The way I see It, we need to be way more progressive about technology in this anthropocene age. I think we in this community should push more to surpass that obstacle in a responsible manner.”</em></p><p>Alex Nielsen from <a href="https://rebbls.dk/">REBBLS</a>.</p><p>Based on these discussions we encourage you to continue the conversation, and would like to hear from you as we plan for our next event. Please r<a href="https://forms.gle/B5G8FU8FZV7XC7jQ6">egister here</a> for more information on upcoming events and follow the process on our first community whitepaper.</p><p><strong>About BioFutures</strong></p><p>The Biofutures Initiative was co-created by <a href="https://igem.org/">iGEM</a> &amp; <a href="https://hello-tomorrow.org/">Hello Tomorrow</a> as an opportunity for researchers, startups &amp; companies in biotech to meet and discuss what infrastructure is needed to facilitate a sustainable Biofuture in the European Union.</p><p>Biotechnological advances have accelerated over the past two decades. Our ability to read and write DNA has provided us with unprecedented abilities to engineer biology, also known as synthetic biology. Fundamental biotechnologies are increasingly transformed into B2B/B2C products, as well as new medical therapies and diagnostics. We believe that biology will create the next innovation wave and that it has the potential to positively impact many of the Sustainable Development Goals.</p><p>Therefore we will bring together key stakeholders to define priority actions that aim to better connect the EU biotech-ecosystem, promote the expansion of local bioeconomies, prepare and educate future generations.</p><p>We invite biotech startups, corporates, researchers with ideas to strengthen the EU biotech ecosystem to join the initiative. <a href="https://forms.gle/B5G8FU8FZV7XC7jQ6">Register here</a> to receive updates about our activities or to join as ecosystem partner. You can also follow our progress on <a href="https://twitter.com/bio_futures">Twitter</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7eec7a9dd9b2" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Insights into the European Synthetic Biology Ecosystem]]></title>
            <link>https://medium.com/@biofuturesinitiative/insights-into-the-european-synthetic-biology-ecosystem-7c6d916ab90?source=rss-fb90287f2c22------2</link>
            <guid isPermaLink="false">https://medium.com/p/7c6d916ab90</guid>
            <category><![CDATA[biofutures]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[bioeconomy]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[european-union]]></category>
            <dc:creator><![CDATA[BioFutures Initiative]]></dc:creator>
            <pubDate>Wed, 01 Apr 2020 16:33:19 GMT</pubDate>
            <atom:updated>2020-04-02T16:51:53.293Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1SzsesGIm7MPd5HtrPo4XA.png" /></figure><p><em>Where are we and where does the community want to go?</em></p><p>Synthetic Biology (SynBio) is a relatively young discipline described as “designing and constructing <a href="https://en.wikipedia.org/wiki/BioBrick">biological modules</a>, <a href="https://en.wikipedia.org/wiki/Biological_systems">biological systems</a>, and <a href="https://en.wikipedia.org/wiki/Biological_machine">biological machines</a> or, re-design of existing biological systems for useful purposes”. [1]</p><p>After more than 15 years since the first international synthetic biology conference (SB1.0) and first student competition (iGEM) in 2004, the field has accelerated and increasingly translates bio-innovations from the lab into products that impact a wide variety of sectors.</p><p>Biology is one of the most relevant technologies we have because it is not only scalable, but also sustainable. It seamlessly fits into the circular economy we need to protect ourselves from the consequences of climate change while maining a stable economy.</p><p>This is why we, the BioFutures Initiative, believe it is important that we strengthen and support actors in the European ecosystem for synthetic biology. To do this, we organised a first <a href="https://www.deeptechweek.com/agenda-deeptechweek/?oaq%5Buid%5D=49118124">virtual meetup on March 11</a>, with key opinion leaders in synthetic biology / biotechnology to discuss the status of the sector and gather ideas for followup actions.</p><p>To understand the current state of the ecosystem, this first blog shares different observations from the Hello Tomorrow, iGEM, EUSynBios and GASB communities in Europe that were shared during the online BioFutures meeting on 11 March.</p><p><strong>Nadine Bongaerts (Board member @ </strong><a href="https://hello-tomorrow.org/"><strong>Hello Tomorrow</strong></a><strong>):</strong></p><p><strong>European actors in synthetic biology tend to compare the European ecosystem a lot with the ecosystem in the United States, especially at Silicon Valley or Boston. We tend to believe that we’re generally behind. Is this true?</strong></p><p><strong>Nicolas Goeldel (Tech Lead @ </strong><a href="https://hello-tomorrow.org/"><strong>Hello Tomorrow</strong></a><strong>):</strong></p><p>Based on the insights obtained from our research at Hello Tomorrow, we see indeed that the US and China are the global leaders in certain aspects of the biotech ecosystem. For instance, the US is more efficient in turning scientific insights into startups. To be more precise, we found that the US is 3.7 times more efficient than France in turning scientific publications into startups and simultaneously the US also invests three times more per startup on average than France and double than the UK.</p><p>In 2019, together with Startup Genome, we mapped the top 60 life science ecosystems. Looking at the top 20 ecosystems for medical biotech, US-based ecosystems are largely outperforming most European cities, with Silicon Valley and Boston ranking number one and two, respectively.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ce12mtc3DlVVNyk3xnCHCA.png" /><figcaption><a href="https://hello-tomorrow.org/deep-tech-observatory/">https://hello-tomorrow.org/deep-tech-observatory/</a></figcaption></figure><p>Naturally, we observed a correlation between ecosystem size and the position in the ranking. However, well-ranked San Diego is a fairly small ecosystem but it has a relatively high percentage of life science startups, same goes for Lausanne, Bern and Geneva. Small ecosystems can compete if they focus their efforts on one sector.</p><p>Silicon Valley and Boston are far above anybody else when it comes to private capital investment. However, the investor quality (indicating the experience of investors in the field) is pretty much independent of the region. It is something that you find in most ecosystems across US, Europe and Asia.</p><p>If we look at the organisation of the ecosystem, we can see that the US has two very big clusters at the West coast and East coast. Each is naturally formed around scientific excellence such as Stanford University, Harvard and MIT.</p><p>On the other hand, in China, it’s more artificially engineered clusters that dominate the landscape. The government choses to develop science and technology innovation parks and install them across the country.</p><p>In Europe, clustering is not based on physical proximity but happens more around common programs either from the European Union or national programs.</p><p>The hallmarks of another study that we recently did with BCG highlights the risk appetite of entrepreneurs in the US — which is higher than in any other region.</p><p>China‘s big advantage is forming the artificial clusters mentioned before. Through these clusters, they bring the whole development chain from the lab to the market in one place, creating spillovers. Once this science and technology innovation park is set up by the state, the capitalistic system / free market takes over and drives solutions from the lab to the market.</p><p>Compared to this approach, Europe’s organisation looks very scattered.</p><p><strong>Nadine Bongaerts:</strong></p><p><strong>Will, how would you describe the network of iGEM and what kind of insights do you have related to the synthetic biology ecosystem?</strong></p><p><strong>Will Wright </strong>(<strong>Director of Entrepreneurship @ </strong><a href="https://igem.org/"><strong>iGEM Foundation</strong></a><strong>):</strong></p><p>iGEM is the world’s largest synthetic biology community, it includes the 350 most top-notch biolabs globally and we have around 7000 participants every year (everyone from junior researchers all the way down to high schools up into college students, undergraduates and post grads)</p><p>It’s a very interesting network that works with us. For about six months, they record their results and activities in an open wiki.</p><p>Interestingly, what we see are insights from those labs from early-stage research. If you take a collective look, you can see some trends. When you look at these ~300 labs, the teams are able to go from a concept to publication within around six months. So you get a snapshot of 18 months ahead of what you’ll see in publications. That gives us an idea of what is coming in the near future.</p><p>Based on this information, we also see a big push towards the industrialization of biotechnology as a means to solve challenges in food, energy, pest and disease control, carbon capturing, recycling of minerals or advanced healthcare therapies going increasingly towards personalised medicine.</p><p>Within my work for the entrepreneurship activities of iGEM, we don’t only see a correlation of quality of research with the creation of startups, but also that the majority of the startups emerge in high performing clusters. There are still constant spots such as Silicon Valley and Boston that lead in our database (as Nicolas also mentioned). But in Europe, we also have some places like Munich and even Paris where you have a lot of companies starting up.</p><p>That gives hope that it’s just a delayed effect of having these new European functional clusters.</p><p><strong>Nadine Bongaerts:</strong></p><p><strong>Adam, EUSynBios represents a community of early stage researchers in Synthetic Biology, what challenges or opportunities do you observe in this academic circle?</strong></p><p><strong>Adam Amara (Vice President @ </strong><a href="https://www.google.com/search?source=hp&amp;ei=9G53XtuJGu2djLsP5bq_kAo&amp;q=eusynbios&amp;oq=eusynbios&amp;gs_l=psy-ab.3..0i13l4j0i13i10i30j0i13i30l5.1182.2753..2921...0.0..0.81.498.9......0....1..gws-wiz.......0j0i10j0i10i30j0i30j0i13i10.tCNmOr72rw8&amp;ved=0ahUKEwjb06TGnq7oAhXtDmMBHWXdD6IQ4dUDCAk&amp;uact=5"><strong>EUSynBios</strong></a><strong>):</strong></p><p>There are a lot of academic interactions in Europe and there are a lot of collaborations happening as a result.</p><p>As Nicholas pointed out, the European system is very scattered so the collaborations work fairly well on the academic level, but I think that a lot of early stage researchers struggle to see what else is happening beyond academia.</p><p>This is why we need central points of contacts for all European synthetic biologists, so it’s easier to interact with other stakeholders. At the same time, it’s important that this also happens on a national level.</p><p><strong>Nadine Bongaerts:</strong></p><p><strong>Speaking about national associations for synthetic biology, this is a nice bridge to ask Henrik to tell us more about the German Association of Synthetic Biology (GASB).</strong></p><p><strong>Hendrik Cooper (Executive Board Member @ </strong><a href="https://www.synthetischebiologie.org/"><strong>German Association for Synthetic Biology</strong></a><strong>):</strong></p><p>I agree that Europe is very academia-focused. America has this startup mindset embedded academics so they usually focus on research that is problem oriented. They approach research with something in mind that they can potentially spinout.</p><p>Germany’s biggest research investor in synthetic biology would be the Max Planck Institution. They are more focussed on expanding the foundation of knowledge instead of creating new products.</p><p><strong>Nadine Bongaerts:</strong></p><p><strong>Thank you for sharing your insights on the ongoing activities in Europe. However, based on some of the feedback we received from participants, we also noticed that for many people it is not so transparent what is happening. Do you think that there is enough information available? And do you have ideas to strengthen the EU ecosystem?</strong></p><p><strong>Adam Amara:</strong></p><p>That is a very good question because the available information is very different in countries across the European Union. Trying to bring that together is quite difficult and so having complete access is not always easy. Ideally, it would be great to have a central European platform. Of course we’ve been trying to do this as well, but it’s difficult with volunteers of a nonprofit. Something that would be driven from the EU would be useful.</p><p><strong>Hendrik Cooper:</strong></p><p>I think that one of the most important parts to strengthen this European ecosystem is to have more national associations for synthetic biology. I believe it’s almost always easier for you to connect inside of your own country than to someone outside of your country.</p><p><strong>Adam Amara:</strong></p><p>I agree that it is really important to have these national associations and then connect this to a pan-european one.</p><p>If we would only focus on creating a pan-european organisation you miss the connection and insights on a local level.</p><p>I think we could take inspiration from the UK where they have this council where they bring all the different synbio centers from different cities together.</p><p>You have policymakers, industry, startups and academics altogether under this council that helps to drive the strategy for the whole country.</p><p>We should have something like this and then work with organisations like GASB and others to work as one European network.</p><ol><li>Nakano T, Eckford AW, Haraguchi T (12 September 2013). <a href="https://books.google.com/books?id=uVhsAAAAQBAJ">Molecular Communication</a>. Cambridge University Press. <a href="https://en.wikipedia.org/wiki/International_Standard_Book_Number">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/978-1-107-02308-6">978–1–107–02308–6</a>.</li></ol><p><strong>About BioFutures</strong></p><p>The Biofutures Initiative was co-created by <a href="https://igem.org/">iGEM</a> &amp; <a href="https://hello-tomorrow.org/">Hello Tomorrow</a> as an opportunity for researchers, startups &amp; companies in biotech to meet and discuss what infrastructure is needed to facilitate a sustainable Biofuture in the European Union.</p><p>Biotechnological advances have accelerated over the past two decades. Our ability to read and write DNA has provided us with unprecedented abilities to engineer biology, also known as synthetic biology. Fundamental biotechnologies are increasingly transformed into B2B/B2C products, as well as new medical therapies and diagnostics. We believe that biology will create the next innovation wave and that it has the potential to positively impact many of the Sustainable Development Goals.</p><p>Therefore we will bring together key stakeholders to define priority actions that aim to better connect the EU biotech-ecosystem, promote the expansion of local bioeconomies, prepare and educate future generations.</p><p>We invite biotech startups, corporates, researchers with ideas to strengthen the EU biotech ecosystem to join the initiative. <a href="https://forms.gle/B5G8FU8FZV7XC7jQ6">Register here</a> to receive updates about our activities or to join as ecosystem partner. You can also follow us on <a href="https://twitter.com/bio_futures">Twitter</a> :)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7c6d916ab90" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>